Glioblastma multiforme (GBM) is one of the most lethal primary brain tumors, with median survival of the patients, which is only slightly over one year. Researchers at Boston University School of Medicine (BUSM), in collaboration with researchers from the City of Hope, are looking toward novel therapeutic strategies for the treatment of GBM in the form of targeted therapies against a unique receptor, the interleukin-13 receptor (and) #945; chain variant 2 (IL13R (and) #945;2). ...
via Medindia Health News More READ
via Medindia Health News More READ
No comments:
Post a Comment